|
|
3pRNA |
|
Vaxjo ID |
309 |
|
Vaccine Adjuvant Name |
3pRNA |
|
Adjuvant VO ID |
VO_0005270
|
|
Description |
3pRNA is an immune-stimulatory adjuvant that potently improves CTL cross-priming and facilitates antiviral vaccination. It functions by requiring IPS-1/MAVS signaling and inducing type I IFN in plasmacytoid dendritic cells and macrophages. |
|
Stage of Development |
Research |
|
Host Species for Testing |
Mouse |
|
Components |
triphosphate RNA (3pRNA) as especially effective at inducing CTL responses |
|
Structure |
Triphosphate RNA |
|
Function |
3pRNA sensing activates IPS-1/MAVS signaling, triggering type I interferon (IFN) production mainly in macrophages and plasmacytoid dendritic cells, with macrophages playing a key role in the adjuvant effect. Type I IFN acts on CD11c(+) cells, particularly CD8α(+) Batf3-dependent dendritic cells. Vaccination combining OVA with 3pRNA provides strong CD8(+) T cell–dependent protection against OVA-adenovirus infection, outperforming other adjuvants. |
| Related Vaccine(s) |
|
| References |
Hochheiser et al., 2016: Hochheiser K, Klein M, Gottschalk C, Hoss F, Scheu S, Coch C, Hartmann G, Kurts C. Cutting Edge: The RIG-I Ligand 3pRNA Potently Improves CTL Cross-Priming and Facilitates Antiviral Vaccination. Journal of immunology (Baltimore, Md. : 1950). 2016; 196(6); 2439-2443. [PubMed: 26819202].
|
|
